AIM Vaccine (HKG:6660) recently submitted a clinical trial application for its mRNA shingles/herpes zoster vaccine to China's National Medical Products Administration, a Tuesday Hong Kong bourse filing by the drugmaker stated.
Results from a third-party preclinical animal testing study showed the company's mRNA shingles vaccine outperformed commercially-available subunit vaccines in immune response.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.